Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity.

Abstract

BACKGROUND:

Anthracyclines, such as doxorubicin (Adriamycin), are highly effective chemotherapeutic agents, but are well known to cause myocardial dysfunction and life-threatening congestive heart failure (CHF) in some patients.

METHODS:

To generate new hypotheses about its etiology, genome-wide transcript analysis was performed on whole blood RNA from women that received doxorubicin-based chemotherapy and either did, or did not develop CHF, as defined by ejection fractions (EF)≤40%. Women with non-ischemic cardiomyopathy unrelated to chemotherapy were compared to breast cancer patients prior to chemo with normal EF to identify heart failure-related transcripts in women not receiving chemotherapy. Byproducts of oxidative stress in plasma were measured in a subset of patients.

RESULTS:

The results indicate that patients treated with doxorubicin showed sustained elevations in oxidative byproducts in plasma. At the RNA level, women who exhibited low EFs after chemotherapy had 260 transcripts that differed >2-fold (p<0.05) compared to women who received chemo but maintained normal EFs. Most of these transcripts (201) were not altered in non-chemotherapy patients with low EFs. Pathway analysis of the differentially expressed genes indicated enrichment in apoptosis-related transcripts. Notably, women with chemo-induced low EFs had a 4.8-fold decrease in T-cell leukemia/lymphoma 1A (TCL1A) transcripts. TCL1A is expressed in both cardiac and skeletal muscle, and is a known co-activator for AKT, one of the major pro-survival factors for cardiomyocytes. Further, women who developed low EFs had a 2-fold lower level of ABCB1 transcript, encoding the multidrug resistance protein 1 (MDR1), which is an efflux pump for doxorubicin, potentially leading to higher cardiac levels of drug. In vitro studies confirmed that inhibition of MDR1 by verapamil in rat H9C2 cardiomyocytes increased their susceptibility to doxorubicin-induced toxicity.

CONCLUSIONS:

It is proposed that chemo-induced cardiomyopathy may be due to a reduction in TCL1A levels, thereby causing increased apoptotic sensitivity, and leading to reduced cardiac MDR1 levels, causing higher cardiac levels of doxorubicin and intracellular free radicals. If so, screening for TCL1A and MDR1 SNPs or expression level in blood, might identify women at greatest risk of chemo-induced heart failure.

• Authors: Timothy A McCaffrey, Constantine Tziros, Jannet Lewis, Richard Katz, Robert Siegel, William Weglicki, Jay Kramer, I Tong Mak, Ian Toma, Liang Chen, Elizabeth Benas, Alexander Lowitt, Shruti Rao, Linda Witkin, Yi Lian, Yinglei Lai, Zhaoqing Yang, Sidney W Fu
• Journal: International journal of biological sciences (Int J Biol Sci) Vol. 9 Issue 4 Pg. 350-60 ( 2013) ISSN: 1449-2288 [Electronic] Australia
• PMID: 23630447 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ATP Binding Cassette Transporter, Subfamily B, Member 1
• Anthracyclines
• Antineoplastic Agents
• Proto-Oncogene Proteins
• TCL1A protein, human
• Doxorubicin

Topics

• ATP Binding Cassette Transporter, Subfamily B, Member 1 (deficiency, metabolism)
• Animals
• Anthracyclines (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, genetics, metabolism)
• Cardiomyopathies (chemically induced, metabolism)
• Cells, Cultured
• Doxorubicin (adverse effects, therapeutic use)
• Female
• Humans
• Proto-Oncogene Proteins (deficiency, metabolism)
• Rats